Capsugel Receives EU GMP Certificate for Bend Research’s Clinical and Commercial Manufacturing Operations in Bend, Ore.
May, 15, 2017
Morristown, N.J., and Bend, Ore., May 15, 2017 – Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that Sweden’s Medical Products Agency (MPA) recently completed a successful inspection of the company’s Bend Research facility in Bend, Ore., and has granted it an EU GMP certificate.
The inspection covered two commercial products, as well as Capsugel's clinical manufacturing of investigational medicinal products. As part of the inspection, the MPA confirmed that all outstanding items from previous audits have been satisfactorily addressed.
“We are very pleased with the outcome of the MPA’s inspection, and we look forward to continuing to work with our customers to develop and manufacture the high-quality drug products that patients need,” said Anthony Macci, Capsugel’s Sr. Vice President of Global Operations and Managing Director of Bend Research. “The successful inspection demonstrates Capsugel’s commitment to the highest levels of quality, compliance and integrity in all we do.”
Capsugel designs, develops, and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries. Our unique combination of science, engineering, formulation and capsule expertise enables our customers to optimize the bioavailability, targeted delivery and overall performance of their products. We partner with more than 4,000 customers in over 100 countries to create novel, high-quality and customized solutions that align with our customers’ evolving needs and benefit patients and consumers. For more information, visit www.capsugel.com and follow us on Twitter, LinkedIn and YouTube.